News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dr. Reddy's Laboratories Ltd. (RDY)'s Announces the Launch of Clopidogrel Tablets, USP



5/18/2012 10:20:59 AM

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched CLOPIDOGREL TABLETS, USP 75 mg & 300 mg, a bioequivalent generic version of PLAVIX®, in the U.S. market on May 18, 2012. The ANDAs for Clopidogrel Tablets USP, 75 mg & 300 mg are approved by the United States Food & Drug Administration (USFDA). Dr. Reddy’s Laboratories was among the first applicants to submit a substantially complete ANDA for Clopidogrel Tablets USP, 300 mg with a Paragraph IV certification, and was awarded 180 days of marketing exclusivity for this strength.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES